Research progress of mTOR inhibitors for anti-atherosclerosis
- VernacularTitle:mTOR抑制剂抗动脉粥样硬化的研究进展
- Author:
Liqiao LIU
;
Qun WANG
- Keywords:
atherosclerosis;
mTOR;
rapamycin;
rapalogs
- From:
Basic & Clinical Medicine
2017;37(2):265-269
- CountryChina
- Language:Chinese
-
Abstract:
Mammalian target of rapamycin ( mTOR) is a kind of Ser/Thr kinase existing in mammalian cells can regulate cell proliferation, migration and angiogenesis.mTOR including two different complex forms as mTORC1 and mTORC2 .Rapamycin and rapalogs were soon found to have powerful immunosuppressant prop-erties and thus be valuable for preventing the progress of the artery atheromatous by inhibiting the function of mTORC1.But long-term rapalogs administration may increase the side actions such as mTORC1 resistance, mTORC2 inhibition, dyslipidemia.The clinical application of drug combination and dosage optimization may reduce adverse events.
